MassDevice Big 100 Roundtable West 2012 Slideshow page 5
MassDevice Big 100 Roundtable West 2012 Slideshow page 4
MassDevice Big 100 Roundtable West 2012 Slideshow page 3
MassDevice Big 100 Roundtable West 2012 Slideshow page 2
Medical device tax is here to stay, says AdvaMed’s James Mazzo
*Correction Dec. 13, 2012: Mazzo is a member of AdvaMed’s board of directors and he is chairman of the nominating committee.
Forget "cautious optimism" – the 2.3% medical device tax isn’t going anywhere, according to Abbott Medical Optics president and former AdvaMed board chairman James Mazzo.
GPO: Novation awards new deals to medtech giants
Group purchasing organization Novation awarded new cardiovascular contracts to a host of market leaders, effective at the beginning of 2013.
Abbott’s board approves AbbVie pharma spinout | Wall Street Beat
Abbott (NYSE:ABT) said its board of directors approved the spinout of its branded pharmaceuticals business as AbbVie Inc. in which Abbott’s shareholders will receive an AbbVie share for each ABT share they own.
The distribution is slated for Jan. 1, 2013, for shareholders of record as of Dec. 12, according to a press release.
Feds charge ex-baseballer DeCinces with insider trading in Abbott/AMO deal
iCad soars on Medicare reimbursement nod | Wall Street Beat
Open heart surgery beats stents in 5-year Freedom trial
Patients with diabetes and multi-vessel heart disease did better with cardiac bypass surgery than patients treating using drug-eluting stents, according to a 5-year study comparing the therapies.
The Freedom trial found that the CABG arm of the 1,900-patient study had fewer adverse events and lower mortality rates than the percutaneous coronary intervention cohort.